AstraZeneca's Farxiga gets rough FDA review date for groundbreaking move into chronic kidney disease

AstraZeneca's Farxiga gets rough FDA review date for groundbreaking move into chronic kidney disease

Source: 
Endpoints
snippet: 

AstraZeneca’s Farxiga broke ground last year with an FDA nod for heart failure patients with or without type 2 diabetes — a first-in-class approval. But Farxiga isn’t done innovating and is now looking at a approval in the coming months in another potential blockbuster indication.